jCell
Retinitis Pigmentosa
Phase 3Active
Key Facts
About jCyte
jCyte is a private, pre-revenue biotech advancing a proprietary platform of retinal progenitor cell (RPC) therapies for inherited retinal diseases. Its lead asset, jCell, is in late-stage clinical development for retinitis pigmentosa, with a pivotal Phase 3 trial (JC02-88) now enrolling. The company leverages its RPC platform to pursue multiple ophthalmic indications, including diabetic retinopathy, positioning it in the high-need cell and gene therapy space for blindness. Leadership combines strong scientific co-founders with experienced biotech executives to drive clinical and corporate strategy.
View full company profileTherapeutic Areas
Other Retinitis Pigmentosa Drugs
| Drug | Company | Phase |
|---|---|---|
| Endogena Therapeutics Program | Centenara Labs | Phase 1b/2a |
| BS01 | Bionic Sight | Phase 1/2 |
| EA-2353 | Endogena Therapeutics | Phase I/IIa |
| NPI-001 | Nacuity Pharmaceuticals | Phase 2/3 |
| MCO-010 | Nanoscope Therapeutics | Phase 2/3 |
| RTx-015 | Ray Therapeutics | Phase 1 |
| OCU400 | Ocugen | Phase 3 |
| ADX-2191 | Aldeyra Therapeutics | Phase 2 |